Short Bowel Syndrome Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2021 - 2026
Short Bowel Syndrome Market size is valued at $752m in 2019, and is anticipated to grow at a CAGR of 23.3% during the forecast period 2020-2025. The Short Bowel Syndrome Market growth rate is attributed to the increasing public awareness about the generic disorders or bowel related disorders is influencing the vendors and authorities to provide adequate knowledge. Short bowel syndrome is a group of problems related to poor absorption of nutrients. Short bowel syndrome typically occurs in people who have had at least half of their small intestine removed and sometimes all or part of their large intestine removed, significant damage of the small intestine, poor motility, or movement, inside the intestines. The main symptom of short bowel syndrome is diarrhea—loose, watery stools, which can lead to dehydration, malnutrition, and weight loss. From the initiates by many government bodies, pharmaceutical companies, health ministries, and NGOs conduct health programs and camps to educate the people and raise awareness to the market players distributing free samples and kits with the aim of educating the people and promoting their drugs is anticipated to propel the Short Bowel Syndrome Market during the forecast period 2020-2025.
The report: “Short Bowel Syndrome Market Forecast (2020-2025)”, by Industry ARC, covers an in-depth analysis of the following segments of the Short Bowel Syndrome Market:
By Drug Type: GLP-2, Glutamine, Zorbtive, Teduglutide and Others.
By Diagnosis: Physical Exam, Blood Tests, Fecal Fat Tests, Imaging Procedures and Others.
By Treatment: Nutritional Therapy, Medications, Surgery, Transplant.
By Mode of Administration: Parenteral Administration and Oral Administration.
By Distribution Channel: Hospitals, Diagnostics Centers/Multispecialty Clinics, Hospital/Retail Pharmacies, and Others.
By Geography: North America, Europe, Asia-Pacific and RoW.
- North America dominated the Short Bowel Syndrome Market with a share of 36% in the year 2019.
- The factors such as increasing investments made on UHT treatment for other products, increasing production capacities of UHT treatment plants are amongst the major factor projected to impel growth of Short Bowel Syndrome Market.
- Increase in demand for food & beverage products with an extended shelf life, marginal nutritional changes in products such as milk, and reduction in logistics and storage cost are the key factors owing to the growth in the segment during forecast period 2020-2025.
Drug Type - Segment Analysis
GLP-2 drug held the largest share in the market owing to the only products available for treatment with the brand names Gattex, introduced by Takeda which was approved for sales in both the US and Europe respectively. Apart from this, the drugs currently hold the orphan drug status, and the exclusivity of the drugs in the treatment of the short bowel syndrome would further draw huge revenue during the forecast period 2020-2025. The segment is poised to grow at CAGR of 20.4%. Furthermore, the preference by the patients owing to unaffordability and higher expensive parenteral nutrition along with prescription products.
Mode of Administration - Segment Analysis
Parenteral Administration segment held the largest share in the market owing to less cost associated with hospitalization. Also this method is preferred over oral mode owing to ease of administration, rising preference for home care and reduced duration of treatment. Moreover, the associated benefits of this route of administration includes low risk of systemic infection and improved quality of life.
By Geography - Segment Analysis
North America dominated the Short Bowel Syndrome Market with a share of 36% in 2019. The application of Short Bowel Syndrome has grown rapidly over the last few years owing to rise in the sedentary lifestyle that led no time to focus on nutritious and healthy food with increased consumption of unhealthy and junk food, resultant intestinal disorders continues to expand its market. The research grants by the public & private players in the US to fuel the R&D of SBS drugs are to cater the Short Bowel Syndrome Market in the forecast period of 2020-2025. Moreover, the uncontrolled consumption of antibiotics and the recent research activities and investments on R&D in the region of Asia-Pacific is anticipated to bolster the SBS market growth.
Drivers – Short Bowel Syndrome Market
- Rising the number of clinical trials or Pipeline Drugs
With the rise in demand of various drugs, there are various drugs in clinical development pipeline consists of several first-in-class drugs that are effective and safe for short bowel syndrome patients. And as these drugs gets launched, Strong pipeline drugs for short bowel syndrome they can act as a key driver of the market during the forecast period 2020-2025.
Challenges – Short Bowel Syndrome Market
- Dangerous Side Effects Restricts Demand
The major challenge for the market is the side effects of taking drugs that help in the treatment of short bowel syndrome. The most common effects on the health by Revestive or Gattex include cold, nausea, flu, abdominal pain, and headaches. In addition to this it has been found that these medicines can further cause complications in the body such as blockage of the bowel, abnormal cell growth which could for the lead to cancer, polyps in the colon, and inflammation of the gallbladder or blockage of the pancreas.
Short Bowel Syndrome Industry Outlook
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Short Bowel Syndrome Market. In 2019, Short Bowel Syndrome Market share is fragmented by the top ten players present in the market. Short Bowel Syndrome Market top 10 companies are Merck KGaA, Pfizer Inc., Zealand Pharma A/S, Sancilio & Company, Inc., OxThera, Nutrinia Ltd., Ardelyx, Inc., Shire plc (Takeda Pharmaceutical Company Limited), Naia Pharmaceuticals, Inc. and others.
- In May 17, 2019 Takeda Pharmaceuticals, U.S.A., Inc. ("Takeda"), announced today that the U.S. Food and Drug Administration (FDA) approved extending the indication of GATTEX® (teduglutide) for injection to pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who need additional nutrition or fluids from intravenous (IV) feeding (parenteral support).
- In February 10, 2020 Scottish Medicines Consortium accepts Revestive® ▼ (teduglutide) for use in NHS Scotland for adult patients with short bowel syndrome, after previously issuing advice restricting its use to pediatric patients only (aged 1-17 years) in 2018.
1. Short Bowel Syndrome Market Overview
1.1 Definitions and Scope
2. Short Bowel Syndrome Market - Executive Summary
2.1 Market Revenue and Key Trends by Company
2.2 Key trends by Drug Type
2.3 Key trends by Treatment
2.4 Key trends by Geography
3. Short Bowel Syndrome Market – Comparative Analysis
3.1 Product Benchmarking – Key Companies
3.2 Financial Analysis – Key Companies
3.3 Market Value Split by Key Companies
3.4 Patent Analysis – Key Companies
3.5 Pricing Analysis
4. Short Bowel Syndrome Market - Startup Companies Scenario (Premium)
4.1 Key Startup Company Analysis by
4.1.3 Venture Capital and Funding Scenario
5. Short Bowel Syndrome Market – Industry Market Entry Scenario Premium (Premium)
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case Studies of Successful Ventures
6. Short Bowel Syndrome Market Forces
6.1 Market Drivers
6.2 Market Constraints/Challenges
6.3 Porters five force model
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7. Short Bowel Syndrome Market – Strategic Analysis
7.1 Value Chain Analysis
7.2 Opportunities Analysis
7.3 Market Life Cycle
8. Short Bowel Syndrome Market – By Drug Type (Market Size –$Million/$Billion)
9. Short Bowel Syndrome Market – By Diagnosis (Market Size –$Million/$Billion)
9.1 Physical Exam
9.2 Blood Tests
9.3 Fecal Fat Tests
9.4 Imaging Procedures
9.4.1 Computerized Tomography (CT) Scan
9.4.2 Magnetic Resonance Imaging (MRI)
9.4.3 X-ray with a Contrast Material (barium X-ray)
10. Short Bowel Syndrome Market – By Treatment (Market Size –$Million/$Billion)
10.1 Nutritional Therapy
10.1.1 Parenteral Nutrition
10.1.2 Enteral Nutrition
11. Short Bowel Syndrome Market – By Mode of Administration (Market Size –$Million/$Billion)
11.1 Parenteral Administration
11.1.1 Intravenous Infusion
11.1.2 Subcutaneous Injection
12. Short Bowel Syndrome Market – By Distribution Channel (Market Size –$Million/$Billion)
12.2 Diagnostics Centers/Multispecialty Clinics
12.3 Hospital/Retail Pharmacies
13. Short Bowel Syndrome Market - By Geography (Market Size –$Million/$Billion)
13.1 North America
13.2.6 Rest of Europe
13.3.4 South Korea
13.3.5 Australia & New Zealand
13.3.6 Rest of Asia-Pacific
13.4 Rest of the World
13.4.1 Middle East
13.4.3 South America
14. Short Bowel Syndrome Market - Entropy
15. Short Bowel Syndrome Market – Industry/Segment Competition Landscape (Premium)
15.1 Market Share Analysis
15.1.1 Global Market Share – Key Companies
15.1.2 Market Share by Region – Key companies
15.1.3 Market Share by Countries – Key Companies
15.1.4 Best Practices for Companies
16. Short Bowel Syndrome Market – Key Company List by Country Premium (Premium)
17. Short Bowel Syndrome Market Company Analysis
17.1 Company 1
17.2 Company 2
17.3 Company 3
17.4 Company 4
17.5 Company 5
17.6 Company 6
17.7 Company 7
17.8 Company 8
17.9 Company 9
17.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.